Akums Drugs and Pharmaceuticals, an Indian pharmaceutical company, has introduced a groundbreaking room temperature-stable oral suspension of Hydroxyurea, a medication used to manage Sickle Cell Disease (SCD). This innovation eliminates the need for cold storage, making the treatment more accessible and affordable for SCD patients across India.
SCD is a genetic blood disorder that affects tribal populations in India, causing severe pain and complications. Recognizing its significance, the Indian government has prioritized interventions for SCD. Akums' new medication is designed for ease of use, with oral syringes for precise dosing for all age groups.
Traditionally, Hydroxyurea requires refrigeration, posing challenges in areas with limited access to cold storage facilities. Akums' room temperature solution removes this barrier to treatment, ensuring that patients can receive their medication without interruption. The company is committed to providing affordable medication for SCD patients, offering the medication at a fraction of the cost of imported brands.
The current import price for the global brand of Hydroxyurea solution is approximately Rs 77,000, with the added requirement of storage at 2 to 8 degrees Celsius. Akums' innovation addresses these challenges by providing a room temperature-stable oral suspension tailored to the needs of Indian patients.